We present the case of a 74-year-old woman with metastatic lobular carcinoma with an occult breast primary presenting as a suspected ampullary tumor due to its ampullary metastasis. The patient's clinical presentation is of interest in two aspects. First, lobular carcinoma of the breast metastatic to the ampulla is extremely rare. Second, in the absence of a detectable primary lesion, prior history of malignancy, or distinguishing clinical, radiological, and endoscopic features, histopathological assessments are pivotal for arriving at the appropriate diagnosis and for optimizing treatment.
I
nvasive lobular carcinoma (ILC) of the breast accounts for about 15% of breast carcinomas and is the second most common histologic type of invasive breast cancer after invasive ductal carcinoma (IDC). ILC is both clinically and biologically distinct from IDC, particularly in its predilection for metastasis to the gastrointestinal (GI) tract. We present here a case of metastatic lobular carcinoma with an occult breast primary presenting as a suspected ampullary tumor due to its ampullary metastasis.
CASE DESCRIPTION
A 74-year-old woman presented to the emergency department for right hip pain after a fall. She was found to have a closed fracture of the right femoral neck and was taken for repair via right hip hemiarthroplasty the following day. Th e patient complained of persistent, generalized weakness associated with malaise and anorexia. She presented with hypokalemia and markedly elevated liver function test values (Table) . Her white blood cell count was also elevated with reduced hemoglobin and hematocrit levels. Her bilirubin was normal on presentation but became elevated on hospital day 1 and further increased during her stay to a high of 7.5 mg/dL on hospital day 9. Abdominal ultrasound revealed dilatation of the intrahepatic, extrahepatic, common bile, and main pancreatic ducts suspicious for an ampullary malignancy.
Esophagogastroduodenoscopy was attempted. Due to duodenal narrowing, it was not possible to pass the endoscope.
Biopsies of the narrowed portion of the duodenum were obtained. Computed tomography scans of the abdomen and pelvis showed marked dilatation and obstruction of both the common duct and pancreatic ducts near the ampulla. A percutaneous biliary drain was placed with subsequent improvement in her liver function tests.
Lobular carcinoma of the breast with gastrointestinal metastasis
Catherine Jones, MD, Alex W. Tong, PhD, Mariam Mir, MD, and Yvonne Coyle, MD Histology results demonstrated a poorly diff erentiated carcinoma with highly atypical cells, some of which were present in cohesive clusters, with others invading in a single fi le manner (Figure 1) . Th e cells were positive for cytokeratin (CK) 7, estrogen receptor (ER; 40%), BRST-2/GCDFP-15 (gross cystic disease fl uid protein-15), mammoglobin, and the transcription factor GATA-3 (trans-acting T-cell-specifi c transcription factor GATA-3). Positron emission tomography showed activity around the distal bile duct, duodenum, and in one left axillary lymph node. Th e patient's fi nal pathology confi rmed the presence of a poorly diff erentiated adenocarcinoma with an immunophenotype of CK7 + , CK19 + , GATA3 + ; CK20 -, and CDX2 -, consistent with a poorly diff erentiated adenocarcinoma of breast primary (Figure 2 ). and human epidermal growth factor receptor 2 (HER2/neu) were negative by immunohistochemistry ( Figure 3 ) with a proliferative fraction of 20%. E-cadherin staining was also performed and was negative within the tumor (Figure 4 ). Approximately 1 month after the patient's original admission and diagnosis, she was readmitted with a small bowel obstruction requiring surgical intervention. Intraoperatively a wedge biopsy of one of the liver lesions was obtained. Th is biopsy was consistent with the prior biopsy, staining positive for CK7, ER (40%), BRST-2/GCDFP-15, and GATA-3. Furthermore, HER2/neu evaluation by fl uorescence in situ hybridization was negative.
Th e patient did not have a family history of breast cancer. She did not have a prior history of lobular carcinoma in situ and had not been on hormonal replacement therapy. Serum levels of carcinoembryonic antigen and CA-125 prior to her initial biopsy were within normal range (Table) . CA 19-9 was elevated (Table) with concomitantly increased bilirubin (6.7 mg/dL), a fi nding that is not uncommon within the context of bile duct obstruction. Serum CA 27-29 determined after initial biopsy was also elevated. Morphologically, the tumor was consistent with a breast primary. Th ere was no evidence of ovarian malignancy by transvaginal ultrasound.
DISCUSSION
An estimated 232,670 new cases of invasive breast cancer are expected to be diagnosed among US women in 2014 (1). ILCs, the second most common histological subset after IDCs, constitute up to 15% of all invasive breast carcinomas, and their incidence has been increasing in the last two decades (2) . Th e higher incidence may be attributable to the increased use of combined hormonal replacement therapy (2) . As a whole, primary breast cancers that metastasize to the GI tract are rare, particularly so at the time of initial diagnosis (3) .
Th e clinical manifestations of breast cancer patients who present with GI metastasis are typically vague. Th e stomach is a commonly reported site of lobular carcinoma metastasis presenting as "linitis plastica" and mimicking primary gastric carcinomas (4), as exemplifi ed by the proband, clinical, radiological, and endoscopic fi ndings overlapping extensively with those found with primary GI malignancies. In these cases, correct identifi cation of the primary tumor origin is essential, with immunohistochemical fi ndings becoming pivotal for an accurate diff erential diagnosis.
Treatment varies considerably for a primary GI malignancy versus a metastatic breast carcinoma. Surgery would most likely be pursued in the case of a primary GI malignancy, but is not considered as clinically benefi cial for patients with a metastatic breast malignancy (4). Treatment of metastatic breast cancer is generally nonsurgical, requiring some form of systemic therapy with cytotoxic chemotherapy, biologic agents in the setting of HER2-neu positivity, or antiestrogen-targeted treatment (5) . Given the noncurative nature of the disease, selection of systemic therapy is based on prolonging survival while minimizing toxicities (5) . For this reason, endocrine therapy is the preferred initial treatment.
Most ILCs express estrogen receptor and lack HER2/ neu expression/gene amplifi cation, hence falling into the "luminal" molecular subgroup (6, 7) . Hormonal receptor expression by the proband is consistent with this profi le. However, increased ER and PR have also been described in gastric adenocarcinomas in limited series (8) . CK7 and CK20 are among the most useful cytokeratin biomarkers for distinguishing carcinomas of unknown origin (9) . Th e CK7 + /CK20 -phenotype is expressed in most breast, lung, and ovarian adenocarcinomas, whereas most intestinal adenocarcinomas and Merkel cell carcinomas are CK7 -/CK20 + (9) . Metastatic breast cancer cells also express CK19, a biomarker that is of high sensitivity but limited specifi city for breast cancers (10) . Conversely, homeobox protein CDX2 expression commonly favors a GI cancer phenotype, as seen in 97% of colorectal cancers, 61% of gastric cancers, and 16% of pancreatic cancers (9), although adenocarcinomas of the ampulla of Vater may also be CDX2-negative (11) . BRST-2 has been shown in multiple studies to be expressed primarily in breast cancers and not in GI cancers (12) . In a recent systemic review of 2500 epithelial and nonepithelial tumors, Miettinen (13) showed that >90% of primary and metastatic breast ductal and lobular carcinomas express the multispecifi c transcription factor GATA3. To a lesser extent, pancreatic ductal carcinomas (37%) and adenocarcinomas of the lung, stomach, and colon (<10%) are GATA3 + . Since >90% of invasive lobular breast carcinomas are ER + and neuroendocrine tumors of GI origin are not (14) , the fi ndings of CK7 + /CK19 + / CK20 -/CDX2 -with positive ER, BRST-2, and GATA-3 expression support the diagnosis of metastatic breast adenocarcinoma, as opposed to a primary adenocarcinoma of ampullary origin (15) . Biopsy morphology and a normal serum CA-125 level in the proband were not consistent with a metastatic ovarian malignancy.
PR expression is also supportive of a non-GI primary; however, in the case of our patient, this was negative. While a negative PR phenotype did not assist in confi rming the breast origin of the patient's malignancy, there is some evidence to support its prognostic value, as PR expression is inversely associated with breast cancer stage at diagnosis (7) and a higher risk of relapse and death (16) . Additionally, PR status is predictive of potential benefi t from endocrine therapy (16, 17) , where PR-positive breast cancer patients demonstrate a reduced risk for disease recurrence and death compared to PR-negative patients (16) .
Negative expression of the epithelial calcium-dependent adhesion molecule E-cadherin has been shown to be a sensitive and specifi c biomarker to confi rm the invasive lobular carcinoma subtype among tumors with histologically equivocal features (18, 19) . Aberrant expression of the E-cadherin-β-catenin complex is an early event that aff ects typical lobular hyperplasia as well as lobular carcinoma in situ (19) . Invasive lobular breast carcinomas are typically E-cadherin-negative, which indicates that loss of cell-cell adhesion promotes lobular carcinoma metastases (18, 19) . In contrast, aberrancy in E-cadherin gene expression appears to manifest epigenetically among IDCs. IDCs generally demonstrate positive immunohistochemical staining related to E-cadherin, albeit weaker as compared with the primary tumor (20) .
